Defunct Company
Total Trials
7
As Lead Sponsor
6
As Collaborator
1
Total Enrollment
1,024
NCT01263236
A Study of LY2940094 in Major Depressive Disorder
Phase: Phase 1
Role: Lead Sponsor
Start: Dec 31, 2010
Completion: Sep 30, 2011
NCT01404091
A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects
Start: Jul 31, 2011
Completion: Nov 30, 2011
NCT01724112
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
Phase: Phase 2
Start: Nov 30, 2012
Completion: Mar 31, 2014
NCT01798303
A Study of LY2940094 in Participants With Alcohol Dependency
Start: Jul 31, 2013
Completion: Jun 30, 2014
NCT03193398
BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
Start: Jun 12, 2017
Completion: Dec 12, 2018
NCT04274660
Evaluation of Diabetes and WELLbeing Programme
Phase: N/A
Role: Collaborator
Start: Sep 8, 2017
Completion: Dec 31, 2022
NCT03608371
BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations
Start: Aug 31, 2018
Completion: Apr 23, 2019